PCSK9 and neoplasm: Importantly, reintroducing PCSK9 restored the tumorigenic abilities of PCSK9KO B16F10 cells, negating potential off-target effects of CRISPR-Cas9 editing as the cause of the observed delayed tumor growth.34 These experimental findings suggest that PCSK9 depletion using CRISPR-Cas9 technology holds potential as an effective antitumor strategy.